Schedule 13D ownership disclosure

Prelude Therapeutics, Inc.

Security class unavailable · CUSIP: 74065P101

Event date: 2021-01-11

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
Unavailable
Percent of class
31.9000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000947871-21-000059
Form type
SC 13D/A
Filer
ORBIMED ADVISORS LLC
CIK
CIK 1055951
Filed
Jan 14, 2021
Reporting period
Jan 11, 2021
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub